OncoHost, a technology company advancing precision medicine through plasma proteomics and artificial intelligence, has announced that it has received a laboratory permit from the New York State Department of Health’s Wadsworth Center. This authorization enables the company to offer its PROphetNSCLC® test to physicians and patients throughout New York, marking a significant milestone in OncoHost’s U.S. expansion efforts.
The New York State Department of Health’s certification underscores the high standards required for clinical laboratory operations, further affirming OncoHost’s commitment to quality, accuracy, and regulatory compliance.
OncoHost’s proprietary PROphet® platform leverages AI-driven proteomic profiling to support first-line treatment decisions in oncology. Its flagship test, PROphetNSCLC®, commercially available since 2023, assists oncologists in managing patients with metastatic non-small cell lung cancer (mNSCLC). Using a single blood sample, the test evaluates thousands of plasma proteins to predict a patient’s likelihood of responding to PD-1/PD-L1 inhibitors, helping physicians personalize therapy and enhance outcomes.
“This permit is a significant step forward in making precision oncology accessible to more patients,” said Ofer Sharon, MD, CEO of OncoHost. “New York State maintains some of the most stringent laboratory certification requirements in the U.S., and meeting these standards underscores our scientific rigor, operational excellence, and dedication to clinical impact.”
The new certification adds to OncoHost’s existing Clinical Laboratory Improvement Amendments (CLIA) certification and College of American Pathologists (CAP) accreditation, further strengthening its laboratory network and nationwide testing capabilities.
“Receiving this permit allows us to serve one of the nation’s largest and most diverse patient populations,” said Amir Gelman, PhD, Director of Laboratory Operations & Assay Development at OncoHost. “We’re proud to deliver reliable, high-quality testing that supports oncologists in making data-driven decisions for their patients.”
With this latest regulatory milestone, PROphetNSCLC® is now officially available for clinical use across all 50 U.S. states.
Also Read